Novartis names new US pharma chief

Share this article:
Novartis confirmed in published reports today that it has appointed Ludwig Hantson to head its US pharmaceuticals business. 

Hantson reports to Joe Jimenez, CEO of the Basel, Switzerland-based company's pharmaceutical business. Hantson replaces Alex Gorsky, who announced he was leaving Novartis in February. 
Hantson most recently served as head of Novartis' specialty pharmaceuticals unit in the US, where he has worked since December 2006. 

Novartis also said Paulo Costa, president and CEO of Novartis' US unit, will retire June 30 and be replaced by Gary Rosenthal. Rosenthal is currently CFO of the US pharmaceuticals business. 
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union